Skip to Content
MilliporeSigma
  • Expression and activation of caspase 3 following status epilepticus in the rat.

Expression and activation of caspase 3 following status epilepticus in the rat.

The European journal of neuroscience (2003-09-27)
Susanna Narkilahti, Terhi J Pirttilä, Katarzyna Lukasiuk, Jarkko Tuunanen, Asla Pitkänen
ABSTRACT

It is in dispute whether caspase 3 contributes to status epilepticus (SE)-induced cell loss. We hypothesized that caspase 3-mediated cell death continues beyond the acute phase of SE. We induced SE with either kainic acid or electrical stimulation of the amygdala in Wistar and Sprague-Dawley rats. Caspase 3 immunohistochemistry, Western blot analysis and enzyme activity measurements were used to determine cellular localization and the time course of caspase 3 expression and activation. Immunohistochemistry indicated that caspase 3 protein expression increased following SE, peaking at 16-24 h. Cleavage of procaspase 3 to active fragments (p20-17) was detected 2-7 days after SE. Caspase 3 enzyme activity was elevated at 8 h and further increased up to 19.4-fold at 7 days following SE. Activation of caspase 3 after SE occurred in the hippocampus and the extrahippocampal temporal lobe but not in the thalamus. Caspase 3-immunoreactive cells represented only a minority of degenerating cells as assessed by Fluoro-Jade B and TUNEL staining. Analysis of double-labelled sections indicated that active caspase 3 was located in astrocytes rather than neurons or microglia. There was increased caspase 3 expression in both rat strains, and it was independent of the method used to induce SE. These data demonstrate that caspase 3 contributes to the cell death occurring within the first week after SE, but in only a small proportion of degenerating cells. These results suggest that, contrary to expectations, caspase 3 inhibitors would have only limited benefits in the treatment of SE.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Caspase-3 Inhibitor II, The Caspase-3 Inhibitor II, also referenced under CAS 210344-95-9, controls the biological activity of Caspase-3. This small molecule/inhibitor is primarily used for Cancer applications.